Springtail | $2,500,000 | (Apr 10, 2025)
Ryft | $7,315,294 | (Apr 10, 2025)
Ottometric | $10,000,000 | (Apr 10, 2025)
Certified by Founder
Lodge
Myrobalan Therapeutics
start up
United States
- Medford, Massachusetts
- 11/01/2024
- Series A
- $24,000,000
Developing therapeutics to address the unmet need and societal burdens posed by neurodegenerative, demyelinating and neuropsychiatric disorders.
- Industry Biotechnology Research
- Website https://myrotx.com/
- LinkedIn https://www.linkedin.com/company/myrobalantx/about/
Merida Biosciences | $121,000,000 | (Apr 10, 2025)
DIAMO | $4,000,000 | (Apr 10, 2025)
Rondah AI | $1,800,000 | (Apr 10, 2025)
Pax | $4,500,000 | (Apr 10, 2025)
Luzern Risk | $12,000,000 | (Apr 10, 2025)
Adaptis | $4,000,000 | (Apr 9, 2025)
Sipay | $78,000,000 | (Apr 9, 2025)
Gallatin AI | $15,000,000 | (Apr 9, 2025)
Rain(1) | $75,000,000 | (Apr 9, 2025)